

EDITORIAL

Open Access



The KT Jeang Retrovirology prize 2022: Florence Margottin-Goguet

Retrovirology Editorial*



Florence Margottin-Goguet studied cellular and molecular biology at the University Pierre and Marie Curie in Paris. As a PhD student, she worked from 1989 to 1993 in the laboratory directed by André Sentenac in Saclay,

near Paris. Sentenac's lab was internationally recognized in the field of transcription research using the *Saccharomyces cerevisiae* as a model organism. Specifically, the laboratory focused on the isolation of the essential components of the transcription machinery as well as on the elucidation of the mechanisms underlying transcription activation. Florence first worked under the guidance of Dr. Geneviève Dujardin and Dr. André Sentenac. She was involved in the discovery that TAT-binding factor (TBP) is required for the initiation of RNA polymerase 3-mediated transcription, and is therefore not only a cofactor of RNA polymerase 2 as was thought at the time [1]. Later on, TBP was found to be an essential factor in gene transcription regardless of the type of RNA polymerase involved.

During her doctoral studies, Florence also collaborated with Anne-Françoise Burnol. Together, they showed that TFIIC, a multi-subunit complex required for the recruitment of RNA polymerase 3 to genes, was involved in the relief of transcription repression by chromatin [2]. This work, which was performed under the expert guidance of Geneviève Almouzni and Marcel Méchali, was Florence's first introduction to the regulation of gene expression in a chromatin environment. Altogether, at the beginning of her career, Florence experienced the common fate of biochemists: long hours in the cold room loading protein extracts onto various types of chromatography columns, harvesting numerous protein fractions which were subsequently monitored for their activity in *in vitro* transcriptional assays. During this period, she had the opportunity to meet fundamental research lovers such as Sylvie Camier, Geneviève Dujardin and Anne-Françoise Burnol. These researchers have definitely influenced Florence's vision of research practice: hypothesis-driven studies and well-designed experiments are rewarded by

*Correspondence: editorial@retrovirology.com
London, UK

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

lots of fun. During this time, Florence also met her future husband and, shortly after obtaining her PhD, they both joined the laboratory of molecular parasitology of the Institut Pasteur in Cayenne, French Guiana. In this lab, candidate vaccines against malaria were monitored. This period was a kind of parenthesis during which Florence tackled a totally different type of research. This stay in French Guiana was rich in discoveries both inside and outside the lab where she and her husband very much enjoyed moving up rivers by pirogue and discovering the beautiful rainforest. This was the first of many travels around the world, a second passion of Florence's, besides research.

Back to Paris in 1994, Florence wished to return to fundamental research. She has always been convinced that basic research is a fertile ground for applied science, especially in the medical field. Accordingly, she chose to study HIV-1 and HIV-2 viruses, the etiological agents of AIDS, as well as related simian viruses (SIV). She obtained a post-doc fellowship from SIDACTION (a French association funding a wide range of research projects on AIDS) and joined the lab headed by Richard Benarous, at the Institut Cochin. This institute provided a stimulating environment as several teams were studying various aspects of the HIV virus biology. Richard Benarous was sharing his enthusiasm about a program he had developed to identify the host cell partners of a set of HIV proteins in order to elucidate their mechanisms of action. The so-called "two-hybrid screening" strategy was particularly well-suited to this approach and, in France, Richard's laboratory had been a forerunner in the development of this method, first described by Fields and Song [3]. Florence was assigned the search for partners of the HIV-1 Vpu protein, as a research project. She remembers her first steps in the cell culture room, as she had never cultivated cells before! She also remembers the harsh discussions between teams about the relevance, or rather lack of relevance, of two-hybrid screens in the field of virology!

It had long been shown that HIV-1 Vpu promotes the degradation of CD4, the cell receptor of HIV although the underlying mechanism remained elusive [4]. The two-hybrid screen performed by Florence yielded several Vpu-interacting candidates, including the human homolog of the *Xenopus* β TrCP protein. Thumb-ing through different papers in the nearby laboratory library, Florence discovered that human β TrCP shared a sequence motif with ubiquitin ligases subunits involved in the targeting of proteins to the ubiquitin-mediated proteolysis pathway [5]. Furthermore, in 1993, pioneering work of Martin Scheffner uncovered that the papillomavirus E6 protein uses an ubiquitin ligase to induce the degradation of the p53 tumor suppressor protein [6].

Taken together, these findings led Florence to hypothesize that Vpu bridges CD4 to β TrCP promoting its degradation by an ubiquitin-mediated pathway. Following numerous biochemical experiments demonstrating the existence of the Vpu/CD4/ β TrCP ternary complex, the hypothesis was fully confirmed thanks to the collaboration with Klaus Strebels team at the NIH. The "Vpu- β TrCP story" has indeed provided the first example of ubiquitin ligase hijacking by an HIV auxiliary protein [7]. It has then turned out that hijacking of ubiquitin ligases is a method employed by almost all HIV auxiliary proteins and it is widely used by viruses to elegantly get rid of host factors detrimental to their life cycle. In this mechanism, a viral protein bridges a host ubiquitin ligase to a specific host protein which is not its natural substrate. The hijacking of ubiquitin ligase by HIV auxiliary proteins then became the favorite theme of Florence's research.

β TrCP was the first identified human member of the family of F-box proteins which are adaptors of the Cul-1 ubiquitin ligase complex. Each member of the family has its own specific targets. Still with the precious mentorship of Richard Benarous, Florence contributed to the identification of the first natural substrates selected by β TrCP for subsequent degradation: $\text{I}\kappa\text{B}\alpha$, β Catenin, ATF4, involved in cancer, inflammation and stress response, respectively [8–10]. A hint was the presence in these cellular substrates of a sequence similar to the β TrCP-binding motif present in HIV-1 Vpu, the "DSGXSS motif" (and derivatives). The presence of this linear motif became a very good indicator of β TrCP binding, leading to the identification of hundreds of β TrCP host targets. Based on this example, Florence likes to pinpoint how discoveries in virology may benefit other fields related to different diseases.

In 1998, Florence got a permanent position at INSERM (National Institute for Medical Research in France). In 2000, she moved to Palo Alto along with her husband and their young daughter to join the laboratory of Peter Jackson at Stanford University to tackle the cell cycle field. Going abroad for postdoctoral training after getting a permanent position was not common, but it was so wonderful: no pressure to get a position! But no pressure does not mean nothing happened. In two and a half years, Florence discovered a new mechanism for entering mitosis under the great mentorship of Peter Jackson. She also discovered the west coast of US through many trips in the beautiful national parks and gave birth to her second child at Stanford hospital. Her research project was to elucidate the mechanism of degradation of the mitotic inhibitor Emi1, a key step for entry into mitosis. When Florence left France, she did not anticipate that she would identify a β TrCP-binding motif in the Emi1 protein sequence but this finding

definitively helped! β TrCP was soon identified as the ubiquitin ligase receptor of Emi1 [11, 12].

In 2005, Florence got her own lab, thanks to two grants dedicated to junior researchers, one called “Avenir” (literally the French word for “Future”) from INSERM and the other, from the city hall of Paris. She wished to take advantage of the knowledge gained from her previous work to study interference of HIV auxiliary proteins with cell cycle progression. Vpr, an auxiliary protein of HIV viruses, was known to cause cell cycle arrest specifically at the G2 phase since 1995 (reviewed in Ref. [13]). Florence decided to address two open issues regarding Vpr-mediated cell cycle arrest: the underlying mechanism and the significance for the viral cycle. Rapidly, she was joined by Catherine Transy and both co-directed the team until 2010. Florence and Catherine shared a common interest in the mechanism of ubiquitin ligase hijacking by viral proteins. As mentioned earlier, Florence had discovered that Vpu-mediated degradation of CD4 relies on its ability to recruit the Cullin 1 ubiquitin ligase through interaction with the β TrCP adaptor while Catherine showed that in vivo infection by hepatitis B virus requires direct interaction of HBx viral protein with DDB1, a core component of Cullin 4 ubiquitin ligase [14].

On the one hand, the team provided evidence that Vpu and Vpr viral auxiliary proteins could interact with two different ubiquitin ligases, being either adaptors or substrates of these enzymes [15, 16]. On the other hand, the team identified a missing link in Vpr-induced cell cycle arrest: the direct interaction between Vpr and DCAF1, an adaptor of the Cullin 4 ubiquitin ligase [17]. So far, only downstream steps in Vpr-mediated cell cycle arrest had been characterized.

Both Florence and Catherine were convinced that thorough scientific monitoring is often rewarded. They were first intrigued by Landau’s group report that Vpr promoted the degradation of two uracil DNA-glycosidases involved in DNA repair and interacted with Cullin 1 and Cullin 4 ubiquitin ligase complexes [18]. Was it a clue that Vpr might hijack Cullin 1 or Cullin 4 ubiquitin ligases to promote the degradation of a host protein required for mitosis entry. Another hint arose from their routine habit to scrutinize any new publication regarding Cullin-based ubiquitin ligases. It turned out that among the recently described DCAF family of Cullin 4 ligase adaptors [19, 20] (others cited in Ref. [17]), DCAF1 had been previously isolated in 1994 by Zhao et al. as a Vpr-binding protein [21]! Everyone in the team rolled up their sleeves and evidence for DCAF1 being a critical player in Vpr-mediated cell cycle arrest quickly accumulated.

The results were published in “Cell Cycle”, after editors of other journals had rejected the manuscript

before any reviewing process. At the time, Cell Cycle was a recent journal that advertised for quick review of “hot” manuscripts. It turned out that Florence’s paper was indeed very hot since five similar studies were published the same year [13]. However, among these published studies, only the Cell Cycle publication addressed whether interaction with DCAF1 was shared by Vpx, a Vpr-related protein found exclusively in HIV-2 and simian viruses. This being the case, it was intriguing: Vpx, in contrast to Vpr, showed no effect on cell cycle but was ascribed an essential role in productive infection of resting myeloid cells. Therefore, Florence and Catherine raised the hypothesis that during their evolution, Vpr and Vpx conserved the use of the DCAF1 ubiquitin ligase but diverged as for the selection of host proteins targeted for degradation, which in turn ensured distinct biological activities. The dependence of DCAF1 for Vpx activity was further demonstrated by the Skowronski and Stevenson’s groups, and then by Florence’s team in collaboration with Gianfranco Pancino’s team [22–24]. Florence loves telling this “Cell Cycle story”: journal with a small impact factor, but high impact in the field as shown by the strong competition that followed! Nonetheless, the team encountered some difficulties for recognition and funding; the steamroller of journal impact factors was harmful! Fortunately, the two AIDS French agencies, SIDACTION and ANRS, kept providing financial support.

The current view was (and still is) that during the so-called arms race between a virus and its host, the latter evolves endogenous factors that restrict productive infection sometimes very potently. Under this selective pressure, the virus in turn evolves countermeasures to escape host restriction. In the HIV field, Malim’s group was a pioneer in the identification of such a host-virus relationship: the Vif auxiliary protein targets APOBEC3G for degradation thus escaping APOBEC3G-mediated editing of the viral genome [25, 26]. The host proteins that provide innate defense against viruses are termed “restriction factors” [27].

As already mentioned, the Vpr/Vpx field became highly competitive, several teams aiming at identifying Vpr and Vpx host targets which were expected to be new restriction factors.

In other words, the Vpr/Vpx treasure hunt had begun! Florence remembers discussions at the bar during the Cold Spring Harbor Laboratory meetings to get clues about what could be the myeloid restriction factor (degraded by Vpx) or the G2 arrest target (degraded by Vpr).

At the time, the “Tap-Tag” (Tandem affinity purification) was considered the method of choice to identify cellular interacting partners of a given (viral) protein. Using

this method, her team succeeded in pulling down all subunits of the E3 ubiquitin ligase hijacked by Vpr but found no convincing host substrates.

In the meantime, in 2009, the “dNTP hypothesis” came out, thanks to Catherine: what if Vpx could enhance macrophage infection by increasing the pool of deoxynucleotides?

Again, surveying the literature, rather old in this case, was inspiring: it was shown that in resting myeloid cells -where Vpx operates- the short supply in deoxynucleotides (dNTP) was a limiting factor in HIV-1 infection [28, 29]. On the other hand, elegant work from the Cimarelli’s group showed that addition of viral pseudo-particles containing SIV Vpx into the cell culture medium strongly enhanced dendritic cells infection by HIV-1 [30]. It was an unexpected and intriguing observation given the absence of a Vpx gene in the HIV-1 genome. Experiments conducted by Florence’s team soon confirmed that when exogenously provided, dNTPs and Vpx had very similar effects i.e. dramatic increase in the number of infected cells and in the speed of the reverse transcription step as well as the ability to act on distinct viruses.

The study was in progress to demonstrate that Vpx increased the endogenous pool of dNTPs in macrophages, thanks to the expertise of Beak Kim. However, the team was taken aback when Benkirane’s and Skowronski’s groups reported the identification of SAMHD1 as the myeloid restriction factor targeted for degradation by Vpx during the Cold Spring Harbor Symposium in 2011 [31, 32]. The team then immediately noticed that SAMHD1 displayed a HD domain suggesting a dNTPase activity which would support their initial hypothesis. The same year, two studies demonstrated the actual dNTPase activity of SAMHD1 in vitro [33, 34]. Rushing to perform in vivo experiments, the team of Florence, and those of Kim, Benkirane, Landau and Canard conjugated their efforts. Together they showed that SAMHD1 depletes the dNTP pool thereby inhibiting the synthesis of viral DNA in macrophages and that Vpx-mediated degradation of SAMHD1, increases the nucleotide pool, abrogating the restriction [35]. This seminal work received lots of attention in the HIV community, and beyond: SAMHD1 restricts other viruses/pathogens than HIV (some replicating in non-dividing cells via a DNA intermediate) and is a player in carcinogenesis through several mechanisms including its ability to modulate dNTP levels [36]. Later on, Florence put forward the hypothesis that SAMHD1 could be responsible for the early antiviral effect of interferon alpha. However, this was not the case as shown simultaneously by Florence’s team and Malim’s team in *Retrovirology* [37, 38].

In 2012, Florence and Claudine Pique merged their teams to create a new research unit at Institut Cochin,

which was named “Retrovirus, Infection and Latency”. The team focuses on the two human pathogenic retroviruses, HIV and HTLV-1, the latter being the only human retrovirus associated to cancer development, specifically adult T-cell leukemia.

Florence’s team pursued the idea of identifying new restriction factors. At the time, Florence thought that the role of Vpx was nearly fully understood. In striking contrast, the genuine function of Vpr in viral infection as well as the precise mechanism of Vpr-mediated cell cycle arrest remained to be elucidated: the relevant host proteins targeted for degradation by Vpr were still missing. Therefore, Florence did not want to give up on Vpr and kept in mind that a given viral protein may be endowed with the ability of targeting several host proteins thereby gaining distinct functions beneficial for the virus.

However, none of the potential Vpr host targets isolated from large scale immunoprecipitations and two-hybrid screens met the expected criteria [such as its depletion triggers G2 arrest and provides an advantage to the virus in macrophages]. Therefore, the team turned to another method termed SILAC (stable isotope labelling by amino acids in cell culture). This method aims at identifying proteins whose levels significantly vary in response to specific treatments, here incubation with viral pseudo-particles containing Vpr. Treatment with Vpx-containing viral pseudo-particles was meant as a control addressing both sensitivity and specificity of the method. Results were encouraging since SAMHD1 was not only retrieved but showed the best decrease ratio [39].

However, SILAC produced very few candidates for Vpr-induced degradation in contrast to the observations recently published by Lehner’s group [40]. Nonetheless, Florence’s team identified the HLTF DNA translocase as a direct target of Vpr-induced degradation, which was simultaneously reported by Skowronski’s group [41, 42]. Somewhat disappointedly, HLTF downregulation failed to cause G2 arrest as expected for a direct player in this Vpr-activity. Thereafter, several cellular proteins were described as degraded by Vpr, some involved in Vpr-mediated G2 arrest, though the overall picture has remained unclear [40, 43, 44].

While Vpr gave everyone strong headaches, the surprise came again from Vpx. A master student in Florence’s lab, Ghina Chougui, exempted from benchwork because of a painful hand tendinitis, was given the project to reclassify the numerous SILAC data generated by the lab according specific criteria. The results highlighted that a host protein, FAM208A (later renamed TASOR), ranked just behind SAMHD1. This protein was previously retrieved in a screen designed to identify new HIV-1 restriction factors by the McKnight’s

group [45]. Right away, Florence hypothesized that TASOR was a restriction factor counteracted by Vpx: TASOR combined antiviral activity with the property of being targeted for degradation by a protein known to use this mechanism against SAMHD1 restriction. The team quite easily confirmed Vpx-mediated degradation of TASOR but lacked clues as for the advantage it might confer to the virus. A corner of the veil was lifted in 2015 when the HUSH complex composed of TASOR, MPP8 and periphilin was reported by the Lehner's group to mediate epigenetic silencing of the HIV-1 provirus in a model of latency as well as silencing of cellular genes and retrotransposons [46]. Using this HIV-1 latency model, Florence's team showed that Vpx as well as the genetically related SIV proteins was able to reactivate the latent virus through HUSH degradation [39]. Thanks to the expertise of Lucie Etienne, phylogenetic and evolutionary analyses highlighted that HUSH antagonism is lentiviral species-specific, which is typical of molecular arms race between restriction factors and viral antagonists, and identified signatures of potential "genetic conflicts" such as multiple isoforms in HUSH [39]. Altogether, on the host side, HUSH has emerged as a key player in the innate response against pathogens, whereas on the virus side, it has come as a surprise that the role of Vpx in viral escape from host restriction is not confined to resting cells. The team has again experienced harsh competition in the area since nearly at the same time, two other groups published similar conclusions about HUSH being a new target of lentiviral proteins [40, 47].

Today, the team is working on the mechanism of HUSH-mediated restriction. Roy Matkovic, a post-doc in the lab, is leading this project. The team has recently discovered that HUSH connects the deposition of repressive epigenetic marks on a HIV-derived transgene to the recognition and degradation of the nascent transcript, describing for the first time in mammalian cells a repressor complex involved in both RNA degradation and epigenetic silencing [48]. Another research axis is currently explored: is HUSH involved in virus persistence in the so-called reservoir cells in HIV carriers [49]? This project stands on a collaboration with a group of several physicians and medical virologists led by Véronique Avettand-Fenoel that recently joined Florence's team. Last but not least, Florence cannot help wondering whether the treasure hunt for Vpr and Vpx targets is over or is just at its beginning... Let's see!

Acknowledgements

Since 2005, the research in Florence's team has been carried out by a series of talented graduate and PhD students (Diana Ayinde, Claire Maudet, Loïc Dragin, Benoit Lacombe, Ghina Chougui, Michael Martin, Angélique Lasserre, Pauline Larrous), postdoctoral fellows (Erwann Le Rouzic, Hichem Lahouassa, Marie-Lise Blondot, Soundasse Munir-Matloob, Virginie Vauthier,

Roy Matkovic), one permanent researcher (Bertha Cecilia Ramirez), temporary "assistant-engineers" (Nadia Belaïdouni, Matthieu Bertrand, Adèle Sourisce) and Marina Morel, a permanent "assistant-engineer", who has contributed to the success of the lab for more than 10 years. Florence's team has been awarded twice by FRM (Foundation for medical research in France). In addition, her team is funded by ANRS and SIDACTION.

Authors contributions

All authors have read and approved the final manuscript.

Declarations

Competing interests

The authors declare that they have no competing interests.

Author details

¹London, UK.

Published online: 06 September 2022

References

- Margottin F, Dujardin G, Gerard M, Egly JM, Huet J, Sentenac A. Participation of the TATA factor in transcription of the yeast U6 gene by RNA polymerase C. *Science*. 1991;251:424–6.
- Burnol AF, Margottin F, Huet J, Almouzni G, Prioleau MN, Mechali M, Sentenac A. TFIIC relieves repression of U6 snRNA transcription by chromatin. *Nature*. 1993;362:475–7.
- Fields S, Song O. A novel genetic system to detect protein-protein interactions. *Nature*. 1989;340:245–6.
- Willey RL, Maldarelli F, Martin MA, Strebel K. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. *J Virol*. 1992;66:7193–200.
- Bai C, Sen P, Hofmann K, Ma L, Goebel M, Harper JW, Elledge SJ. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. *Cell*. 1996;86:263–74.
- Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. *Cell*. 1993;75:495–505.
- Margottin F, Bour SP, Durand H, Selig L, Benichou S, Richard V, Thomas D, Strebel K, Benarous R. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. *Mol Cell*. 1998;1:565–74.
- Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H, Perret C, Rubinfeld B, Margottin F, Benarous R, Polakis P. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. *Curr Biol*. 1999;9:207–10.
- Kroll M, Margottin F, Kohl A, Renard P, Durand H, Concordet JP, Bachelierie F, Arenzana-Seisdedos F, Benarous R. Inducible degradation of Ikap-alpha by the proteasome requires interaction with the F-box protein h-betaTrCP. *J Biol Chem*. 1999;274:7941–5.
- Lassot I, Segéral E, Berlioz-Torrent C, Durand H, Groussin L, Hai T, Benarous R, Margottin-Goguet F. ATF4 degradation relies on a phosphorylation-dependent interaction with the SCF(betaTrCP) ubiquitin ligase. *Mol Cell Biol*. 2001;21:2192–202.
- Guardavaccaro D, Kudo Y, Boulaire J, Barchi M, Busino L, Donzelli M, Margottin-Goguet F, Jackson PK, Yamasaki L, Pagano M. Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. *Dev Cell*. 2003;4:799–812.
- Margottin-Goguet F, Hsu JY, Loktev A, Hsieh HM, Reimann JD, Jackson PK. Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. *Dev Cell*. 2003;4:813–26.
- Ayinde D, Maudet C, Transy C, Margottin-Goguet F. Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr? *Retrovirology*. 2010;7:35.
- Sitterlin D, Lee TH, Prigent S, Tiollais P, Butel JS, Transy C. Interaction of the UV-damaged DNA-binding protein with hepatitis B virus X protein

- is conserved among mammalian hepadnaviruses and restricted to transactivation-proficient X-insertion mutants. *J Virol.* 1997;71:6194–9.
15. Estrabaud E, Le Rouzic E, Lopez-Verges S, Morel M, Belaidouni N, Benarous R, Transy C, Berlioz-Torrent C, Margottin-Goguet F. Regulated degradation of the HIV-1 Vpr protein through a betaTrCP-independent pathway limits the release of viral particles. *PLoS Pathog.* 2007;3: e104.
 16. Le Rouzic E, Morel M, Ayinde D, Belaidouni N, Letienne J, Transy C, Margottin-Goguet F. Assembly with the Cul4A-DDB1/DCAF1 ubiquitin ligase protects HIV-1 Vpr from proteasomal degradation. *J Biol Chem.* 2008;283:21686–92.
 17. Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, Transy C, Margottin-Goguet F. HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. *Cell Cycle.* 2007;6:182–8.
 18. Schrofelbauer B, Yu Q, Zeitlin SG, Landau NR. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG1 uracil-DNA glycosylases. *J Virol.* 2005;79:10978–87.
 19. Angers S, Li T, Yi X, MacCoss MJ, Moon RT, Zheng N. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. *Nature.* 2006;443:590–3.
 20. He YJ, McCall CM, Hu J, Zeng Y, Xiong Y. DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. *Genes Dev.* 2006;20:2949–54.
 21. Zhao LJ, Mukherjee S, Narayan O. Biochemical mechanism of HIV-1 Vpr function. Specific interaction with a cellular protein. *J Biol Chem.* 1994;269:15577–82.
 22. Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, Descamps D, Damond F, Brun-Vezinet F, Nisole S, et al. The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1/DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection. *J Virol.* 2009;83:4854–60.
 23. Sharova N, Wu Y, Zhu X, Stranska R, Kaushik R, Sharkey M, Stevenson M. Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. *PLoS Pathog.* 2008;4: e1000057.
 24. Srivastava S, Swanson SK, Manel N, Florens L, Washburn MP, Skowronski J. Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection. *PLoS Pathog.* 2008;4: e1000059.
 25. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. *Nature.* 2002;418:646–50.
 26. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. *Nat Med.* 2003;9:1404–7.
 27. Malim MH, Bieniasz PD. HIV restriction factors and mechanisms of evasion. *Cold Spring Harb Perspect Med.* 2012;2: a006940.
 28. Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam AR, Lee KY, Balakrishnan M, Bambara RA, Planelles V, Dewhurst S, Kim B. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. *J Biol Chem.* 2004;279:51545–53.
 29. O'Brien WA, Namazi A, Kalhor H, Mao SH, Zack JA, Chen IS. Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. *J Virol.* 1994;68:1258–63.
 30. Goujon C, Jarrosson-Wuilleme L, Bernaude J, Rigal D, Darlix JL, Cimarelli A. With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). *Gene Ther.* 2006;13:991–4.
 31. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. *Nature.* 2011;474:658–61.
 32. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segéral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. *Nature.* 2011;474:654–7.
 33. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, Walker PA, Kelly G, Haire LF, Yap MW, et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. *Nature.* 2011;480:379–82.
 34. Powell RD, Holland PJ, Hollis T, Perrino FW. Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. *J Biol Chem.* 2011;286:43596–600.
 35. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, Bloch N, Maudet C, Bertrand M, Gramberg T, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. *Nat Immunol.* 2012;13:223–8.
 36. Schott K, Majer C, Bulashevskaya A, Childs L, Schmidt MHH, Rajalingam K, Munder M, Konig R. SAMHD1 in cancer: curse or cure? *J Mol Med (Berl).* 2022;100:351–72.
 37. Dragin L, Nguyen LA, Lahouassa H, Sourisce A, Kim B, Ramirez BC, Margottin-Goguet F. Interferon block to HIV-1 transduction in macrophages despite SAMHD1 degradation and high deoxynucleoside triphosphates supply. *Retrovirology.* 2013;10:30.
 38. Goujon C, Schaller T, Galao RP, Amie SM, Kim B, Olivieri K, Neil SJ, Malim MH. Evidence for IFNalpha-induced, SAMHD1-independent inhibitors of early HIV-1 infection. *Retrovirology.* 2013;10:23.
 39. Chougui G, Munir-Matloob S, Matkovic R, Martin MM, Morel M, Lahouassa H, Leduc M, Ramirez BC, Etienne L, Margottin-Goguet F. HIV-2/SIV viral protein X counteracts HUSH repressor complex. *Nat Microbiol.* 2018;3:891–7.
 40. Greenwood EJD, Williamson JC, Sienkiewicz A, Naamati A, Matheson NJ, Lehner PJ. Promiscuous targeting of cellular proteins by Vpr drives systems-level proteomic remodeling in HIV-1 infection. *Cell Rep.* 2019;27(1579–1596): e1577.
 41. Hrecka K, Hao C, Shun MC, Kaur S, Swanson SK, Florens L, Washburn MP, Skowronski J. HIV-1 and HIV-2 exhibit divergent interactions with HLTf and UNG2 DNA repair proteins. *Proc Natl Acad Sci U S A.* 2016;113:E3921–3930.
 42. Lahouassa H, Blondot ML, Chauveau L, Chougui G, Morel M, Leduc M, Guillonnet F, Ramirez BC, Schwartz O, Margottin-Goguet F. HIV-1 Vpr degrades the HLTf DNA translocase in T cells and macrophages. *Proc Natl Acad Sci U S A.* 2016;113:5311–6.
 43. Fabryova H, Strebel K. Vpr and its cellular interaction partners: r we there yet? *Cells.* 2019;8:1310.
 44. Zhang F, Bieniasz PD. HIV-1 Vpr induces cell cycle arrest and enhances viral gene expression by depleting CCDC137. *Elife.* 2020. <https://doi.org/10.7554/eLife.55806>.
 45. Liu L, Oliveira NM, Cheney KM, Pade C, Dreja H, Bergin AM, Borgdorff V, Beach DH, Bishop CL, Dittmar MT, McKnight A. A whole genome screen for HIV restriction factors. *Retrovirology.* 2011;8:94.
 46. Tchasovnikarova IA, Timms RT, Matheson NJ, Wals K, Antrobus R, Gottgens B, Dougan G, Dawson MA, Lehner PJ. Gene silencing. Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells. *Science.* 2015;348:1481–5.
 47. Yurkovetskiy L, Guney MH, Kim K, Goh SL, McCauley S, Dauphin A, Diehl WE, Luban J. Primate immunodeficiency virus proteins Vpx and Vpr counteract transcriptional repression of proviruses by the HUSH complex. *Nat Microbiol.* 2018;3:1354–61.
 48. Matkovic R, Morel M, Lanciano S, Larrous P, Martin B, Bejjani F, Vauthier V, Hansen MMK, Emiliani S, Cristofari G, et al. TASOR epigenetic repressor cooperates with a CNOT1 RNA degradation pathway to repress HIV. *Nat Commun.* 2022;13:66.
 49. Chougui G, Margottin-Goguet F. HUSH, a Link Between Intrinsic Immunity and HIV Latency. *Front Microbiol.* 2019;10:224.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.